Ovid Therapeutics Inc. (NASDAQ:OVID) has a beta value of 1.88 and has seen 714,417 shares traded in the last trading session. The company, currently valued at $349.6 Million, closed the last trade at $5.52 per share which meant it lost -$0.17 on the day or -2.99% during that session. The OVID stock price is -70.29% off its 52-week high price of $9.4 and 67.39% above the 52-week low of $1.8. If we look at the company’s 10-day average daily trading volume, we find that it stood at 535.94 Million shares traded. The 3-month trading volume is 980.23 Million shares.
The consensus among analysts is that Ovid Therapeutics Inc. (OVID) is a Buy stock at the moment, with a recommendation rating of 1.6. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 7 have rated it as a Hold, with 7 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.36.
Ovid Therapeutics Inc. (NASDAQ:OVID) trade information
Despite being -2.99% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Wednesday, Oct 14 when the OVID stock price touched $5.86-5 or saw a rise of 5.81%. Year-to-date, Ovid Therapeutics Inc. shares have moved 33.01%, while the 5-day performance has seen it change -2.3%. Over the past 30 days, the shares of Ovid Therapeutics Inc. (NASDAQ:OVID) have changed -16.62%. Short interest in the company has seen 4.24 Million shares shorted with days to cover at 0.
Wall Street analysts have a consensus price target for the stock at $14.83, which means that the shares’ value could jump 168.66% from current levels. The projected low price target is $10 while the price target rests at a high of $21. In that case, then, we find that the current price level is +280.43% off the targeted high while a plunge would see the stock lose 81.16% from current levels.
Ovid Therapeutics Inc. (OVID) estimates and forecasts
Earnings growth for 2020 is a modest +26.9%.
Ovid Therapeutics Inc. (NASDAQ:OVID)’s Major holders
Insiders own 41.03% of the company shares, while shares held by institutions stand at 33.28% with a share float percentage of 56.43%. Investors are also buoyed by the number of investors in a company, with Ovid Therapeutics Inc. having a total of 78 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 2.91 Million shares worth more than $21.48 Million. As of June 29, 2020, Blackrock Inc. held 5.11% of shares outstanding.
The other major institutional holder is Consonance Capital Management LP, with the holding of over 2.57 Million shares as of June 29, 2020. The firm’s total holdings are worth over $18.95 Million and represent 4.5% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Select Portfolios – Biotechnology and Vanguard Total Stock Market Index Fund. As of July 30, 2020, the former fund manager holds about 3.19% shares in the company for having 1822543 shares of worth $11.76 Million while later fund manager owns 1.18 Million shares of worth $8.68 Million as of June 29, 2020, which makes it owner of about 2.06% of company’s outstanding stock.